The C-C bond hydrolase, HsaD, has a serine protease-like

catalytic triad. We tested a range of serine protease and esterase inhibitors for their effects on HsaD activity. As well as providing a potential starting point for drug development, the data provides evidence for the mechanism of C-C bond hydrolysis. This screen also provides a route to initiate development of fragment-based inhibitors. Although Mycobacterium tuberculosis has been almost eradicated in the developed world, around 1.4 million people died from the disease in 2011 (WHO, 2012) (95% were in developing countries) and 8.7 million people became infected. Around 3.4% of all cases were multidrug-resistant (MDR-TB) tuberculosis (defined as those with resistance to rifampicin and isoniazid), see more while there were around 25 000 cases of extremely drug-resistant tuberculosis (defined as those MDR-TB which are also resistant to fluoroquinolone and a second-line antitubercular e.g. amikacin). The vital role of cholesterol in the infection cycle of M. tuberculosis is becoming increasingly apparent (Ouellet et al., 2011). Cholesterol is vital for phagocytosis of M. tuberculosis

by macrophage (Peyron et al., 2000) and selleck products also plays an important role as an energy source during bacterial survival within macrophage (Van der Geize et al., 2007). The cholesterol metabolism operon of M. tuberculosis has been identified and includes the genes HsaA-D (Van der Geize et al., 2007). Gene deletion mutants of HsaC and HsaD have shown that these enzymes are required for survival inside macrophage (Rengarajan et al., 2005). As HsaD is an essential gene for survival inside macrophage, it is a promising target for antitubercular therapy. HsaD is a member CYTH4 of the meta-cleavage product (MCP) hydrolase class of enzymes which are a subfamily of the α/β hydrolases (Lack et al.,

2008). HsaD catalyses the cleavage of 4,9-DHSA within the cholesterol metabolism pathway (Van der Geize et al., 2007). HsaD cleaves carbon-carbon bonds via a serine protease-like catalytic triad (Lack et al., 2008, 2010). Three classes of inhibitors were tested for activity against HsaD (Supporting Information, Fig. S1). The largest group was serine protease inhibitors. A number of covalent inhibitors, for example phenylmethylsulphonyl fluoride (PMSF), were tested alongside noncovalent inhibitors, for example benzamidine. Acetylcholinesterases are also members of the α/β hydrolase family and catalyse their reactions via a serine protease-like catalytic triad (Shafferman et al., 1992). A range of acetylcholinesterase-specific inhibitors were also tested, for example neostigmine. Humans have a structural homologue of HsaD called monoglyceride lipase [MGL (Bertrand et al., 2010)]. Like acetylcholinesterases, it shares the same overall fold as HsaD and also acts via a serine protease-like catalytic triad.